These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 29443427)

  • 21. Intravenous immunoglobulin as clinical immune-modulating therapy.
    Gilardin L; Bayry J; Kaveri SV
    CMAJ; 2015 Mar; 187(4):257-264. PubMed ID: 25667260
    [No Abstract]   [Full Text] [Related]  

  • 22. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients.
    Lourari S; Herve C; Doffoel-Hantz V; Meyer N; Bulai-Livideanu C; Viraben R; Maza A; Adoue D; Bedane C; Paul C
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1238-40. PubMed ID: 21054575
    [No Abstract]   [Full Text] [Related]  

  • 23. Current medical treatment of ocular mucous membrane pemphigoid.
    Sobolewska B; Deuter C; Zierhut M
    Ocul Surf; 2013 Oct; 11(4):259-66. PubMed ID: 24112229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review.
    Lytvyn Y; Rahat S; Mufti A; Witol A; Bagit A; Sachdeva M; Yeung J
    J Am Acad Dermatol; 2022 Jul; 87(1):110-120. PubMed ID: 33422625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy.
    Buonavoglia A; Leone P; Dammacco R; Di Lernia G; Petruzzi M; Bonamonte D; Vacca A; Racanelli V; Dammacco F
    Autoimmun Rev; 2019 Apr; 18(4):349-358. PubMed ID: 30738958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Update of Autoimmune Blistering Diseases.
    Kridin K; Ahn C; Huang WC; Ansari A; Sami N
    Dermatol Clin; 2019 Apr; 37(2):215-228. PubMed ID: 30850044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infantile Bullous Pemphigoid Treated Using Intravenous Immunoglobulin: Case Report and Review of the Literature.
    Tekin B; Yücelten AD
    Pediatr Dermatol; 2015; 32(5):723-6. PubMed ID: 26119800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid.
    Taylor J; McMillan R; Shephard M; Setterfield J; Ahmed R; Carrozzo M; Grando S; Mignogna M; Kuten-Shorrer M; Musbah T; Elia A; McGowan R; Kerr AR; Greenberg MS; Hodgson T; Sirois D
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Aug; 120(2):161-71.e20. PubMed ID: 25953640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mucous membrane pemphigoid: a review].
    Bédane C; Doffoel Hantz V
    Ann Dermatol Venereol; 2011 Mar; 138(3):201-8. PubMed ID: 21397149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mucous membrane pemphigoid].
    Holtsche MM; Zillikens D; Schmidt E
    Hautarzt; 2018 Jan; 69(1):67-83. PubMed ID: 29242962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The management of mucous membrane pemphigoid and pemphigus.
    Knudson RM; Kalaaji AN; Bruce AJ
    Dermatol Ther; 2010; 23(3):268-80. PubMed ID: 20597945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.
    Shetty S; Ahmed AR
    J Am Acad Dermatol; 2013 Mar; 68(3):499-506. PubMed ID: 23200198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practice and Educational Gaps in Blistering Disease.
    Ehsani-Chimeh N; Marinkovich MP
    Dermatol Clin; 2016 Jul; 34(3):251-6. PubMed ID: 27363880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Inflammatory diseases of oral mucous membranes].
    Horváth ON; Kapser C; Sárdy M
    Hautarzt; 2016 Oct; 67(10):786-792. PubMed ID: 27576550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease.
    Durrani K; Zakka FR; Ahmed M; Memon M; Siddique SS; Foster CS
    Surv Ophthalmol; 2011; 56(6):474-510. PubMed ID: 22117884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Off-label use of biologicals in the management of inflammatory oral mucosal disease.
    O'Neill ID
    J Oral Pathol Med; 2008 Nov; 37(10):575-81. PubMed ID: 18764859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucous membrane pemphigoid: recent advances.
    Srikumaran D; Akpek EK
    Curr Opin Ophthalmol; 2012 Nov; 23(6):523-7. PubMed ID: 23047169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy.
    Ahmed AR
    Expert Opin Investig Drugs; 2004 Aug; 13(8):1019-32. PubMed ID: 15268639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoglobulins and sepsis.
    Shankar-Hari M; Madsen MB; Turgeon AF
    Intensive Care Med; 2018 Nov; 44(11):1923-1925. PubMed ID: 29349688
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical use of polyvalent immunoglobulins.
    Quinti I; Pesce AM; Bonanni L; Rubino C; Pulvirenti F; Milito C
    Blood Transfus; 2013 Sep; 11 Suppl 4(Suppl 4):s33-9. PubMed ID: 24333311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.